ArticleScientific reports2026
A 5-fluorouracil-loaded BSA-Pd nanozyme inducing ROS burst and mild photothermal therapy for potent eradication of colorectal cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Nanozymes have significant potential in human health applications. However, their use in tumor therapy has been restricted by limitations in tumor targeting and retention. Here, we report a 5-fluorouracil (5-Fu)-loaded BSA-palladium nanozyme (FBP) for synergistic treatment of colorectal cancer. The FBP nanozyme was fabricated by conjugation of bovine serum albumin (BSA) with the chemotherapy drug 5-fluorouracil, followed by thermal reduction-mediated precipitation of palladium nanozymes. The BSA shell enhanced biocompatibility and promoted tumor-targeted accumulation via the enhanced permeability and retention (EPR) effect. The FBP nanozyme exhibited both oxidase- and peroxidase-like properties, generating abundant reactive oxygen species to induce tumor cell death. Furthermore, FBP achieved efficient photothermal conversion under 808 nm laser irradiation, triggering 5-fluorouracil release and suppressing tumor growth by hyperthermia. This FBP-mediated photothermal ability was effective in eliminating tumors with negligible systemic toxicity. The findings demonstrate the efficacy of this novel nanozyme in combined photothermal treatment for colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.